Further Studies in Europe Approves Sputnik V Efficiency against Omicron

Further studies conducted on Sputnik V approved the vaccine against the world emerged Omicron, the leading Russian firm announced on Thursday.

Hugo Pizzi, Professor at Cordoba University in Argentina, said: “The results presented in the Spallanzani Institute study are conclusive and encouraging. Sputnik is an excellent vaccine with many properties."

https://twitter.com/sputnikvaccine/status/1484118525648248832

Sputnik V Omicron neutralization decreased only 8 times compared to the world-famed Pfizer that its neutralization's ability dropped by 20 times, the company cited the study on Twitter.

Moreover, the study also approved the efficiency of Sputnik Light according to data by Spallanzani Institution. 

Last month, Alexander Gintsburg, the director of the Gamaleya Research Institute of Epidemiology and Microbiology, said that the Sputnik V COVID-19 vaccine showed high efficiency against the Omicron variant.

Gintsburg explained that the two-dose Russian vaccine can be effective more than the other vaccine brands such as Pfizer, and Moderna, saying: “Sputnik V has demonstrated 3-7x less of a reduction in virus-neutralizing activity against Omicron as compared to data from other vaccine producers: 11.8 times decrease of VNA for Sputnik V in contrast with 41 times decrease for Pfizer-BioNTech and 49-84 times decrease for Moderna.”

He added that the vaccine can provide long-term protection against severe symptoms by Omicron, revealing: “Sputnik V’s long-lasting T-cell immunity contributes to 80% efficacy against Delta on months 6-8 compared with the efficacy of less than 29% demonstrated by certain mRNA vaccines after 6 months.”